Data Sheet (Cat.No.T16410)

TargetMol

Otamixaban

Chemical Properties

CAS No. : 193153-04-7

Formula: C25H26N4O4

Molecular Weight: 446.5

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	Otamixaban (FXV673) is a selective and highly effective Xa inhibitor that inhibits the generation of thrombin and can be used to study acute coronary syndrome.
Targets(IC50)	Factor Xa
In vitro	The HTS assay indicates that otamixaban shows inhibitory activity against TMPRSS2. IC50= 18.7 × 10 μM. Otamixaban in the Calu-3 cell line inhibits SARS-CoV-2 S-mediated viral entry. [5]
In vivo	Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis showed in vivo experiments. Recent clinical findings indicate that Otamixaban is efficacious, safe, and well-tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome.

Solubility Information

Solubility	DMSO: 40 mg/mL (89.59 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.48 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2396 mL	11.1982 mL	22.3964 mL
5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM	0.224 mL	1.1198 mL	2.2396 mL
50 mM	0.0448 mL	0.224 mL	0.4479 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.
Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5; 374(9692):787-95. Epub 2009 Aug 28
Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81.
Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007
Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481.
Hempel T, et al. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chem Sci. 2021 Aug 26;12(38):12600-12609.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481